Variant · Snv

HRAS G13D

CI-VAR-00001633Explore in graph →NP_005334.1:p.Gly13AspNM_005343.3:c.38G>AClinVar 12604 CIViC 274 rs104894226

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm2
HRAS G13D	Cetuximab	Predictive	D	Supports Resistance	—	accepted	EID3852 In an in vitro study, Colo-320, SW48, and CaCO2 cell lines expressing HRAS G13D mutation were associated with resistance to cetuximab treatment, as compared to Colo-320, SW48, and CaCO2 cells expressi… (full text at CIViC) PMID 26561417 · Boidot et al., 2016 · Open in CIViC	civic
HRAS G13D	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	Predictive	C	Supports Resistance	3	accepted	EID699 Case report of a patient with metastatic colorectal carcinoma and a novel HRAS G13D mutation showed resistance to treatment with panitumumab. In vitro models of HRAS G13D confirmed resistance mechanis… (full text at CIViC) PMID 26561417 · Boidot et al., 2016 ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
12604	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Costello syndrome; RASopathy; Non-immune hydrops fetalis; Noonan syndrome and Noonan-related syndrome; Melanoma; Malignant tumor of urinary bladder; Embryonal rhabdomyosarcoma; HRAS-related disorder	germline/somatic	20	Oct 01, 2025	clinvar